Literature DB >> 2196500

Pelvic lymphocele following radical para-aortic and pelvic lymphadenectomy for cervical carcinoma: incidence rate and percutaneous management.

M Conte1, P B Panici, L Guariglia, G Scambia, S Greggi, S Mancuso.   

Abstract

Thirty-six women, treated with radical hysterectomy (Piver types III-IV) plus systematic para-aortic and pelvic lymphadenectomy for cervical carcinoma, underwent serial postoperative ultrasound examinations to determine the incidence of lymphocele and the therapeutic efficacy of percutaneous catheter drainage. Pelvic lymphoceles, ranging in volume from 46-300 mL, occurred in eight patients (22.2%) between the 12-24th postoperative day. Percutaneous catheter drainage, inserted under local anesthesia, was used for a mean time of 14.5 days (range 4-32), resulting in a mean daily drainage of 92.2 mL and a mean total volume of 1727.5 mL per patient. Catheter drainage allowed complete clinical and sonographic remission in all cases, and only one asymptomatic recurrence was observed at 3-month and 6-month follow-up. Ultrasound-guided percutaneous catheter drainage has proved to be a well-tolerated, safe, and effective technique in the management of lymphocele that obviates the need for more invasive surgical procedures.

Entities:  

Mesh:

Year:  1990        PMID: 2196500

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  15 in total

1.  New pattern-based personalized risk stratification system for endocervical adenocarcinoma with important clinical implications and surgical outcome.

Authors:  Andres A Roma; Toni-Ann Mistretta; Andrea Diaz De Vivar; Kay J Park; Isabel Alvarado-Cabrero; Golnar Rasty; Jose G Chanona-Vilchis; Yoshiki Mikami; Sung R Hong; Norihiro Teramoto; Rouba Ali-Fehmi; Denise Barbuto; Joanne K L Rutgers; Elvio G Silva
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

2.  An analysis of the risk factors and management of lymphocele after pelvic lymphadenectomy in patients with gynecologic malignancies.

Authors:  Hee Yeon Kim; Jae Wook Kim; Sung Hoon Kim; Young Tae Kim; Jae Hoon Kim
Journal:  Cancer Res Treat       Date:  2004-12-31       Impact factor: 4.679

3.  Lymphocele and ovarian cancer: risk factors and impact on survival.

Authors:  Tristan Gauthier; Catherine Uzan; Delphine Lefeuvre; Aminata Kane; Geoffroy Canlorbe; Fredéric Deschamps; Catherine Lhomme; Patricia Pautier; Philippe Morice; Sébastien Gouy
Journal:  Oncologist       Date:  2012-06-15

Review 4.  Lymphocele.

Authors:  K S Metcalf; K R Peel
Journal:  Ann R Coll Surg Engl       Date:  1993-11       Impact factor: 1.891

Review 5.  Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in patients with gynaecological malignancies.

Authors:  Kittipat Charoenkwan; Chumnan Kietpeerakool
Journal:  Cochrane Database Syst Rev       Date:  2014-06-04

6.  [Traumatic rupture of a kidney transplant in chronic lymphocele].

Authors:  A Kohler; H P Simmen; W Seelentag; F Largiadèr; O Trentz
Journal:  Langenbecks Arch Chir       Date:  1992

Review 7.  Chylous Ascites and Lymphoceles: Evaluation and Interventions.

Authors:  Ernesto Santos; Amgad M Moussa
Journal:  Semin Intervent Radiol       Date:  2020-07-31       Impact factor: 1.513

8.  Retroperitoneal lymphocele after lumbar total disc replacement: a case report and review of literature.

Authors:  Bibhudendu Mohapatra; Thomas Kishen; Ken W K Loi; Ashish D Diwan
Journal:  SAS J       Date:  2010-09-01

9.  Late aortic lymphocele and residual ovary syndrome after gynecological surgery.

Authors:  Maria Pastore; Natalina Manci; Claudia Marchetti; Francesca Esposito; Marialetizia Iuliano; Lucia Manganaro; Pierluigi Benedetti Panici
Journal:  World J Surg Oncol       Date:  2007-12-28       Impact factor: 2.754

10.  Bleomycin sclerotherapy for severe symptomatic and persistent pelvic lymphocele.

Authors:  Ana Sofia Fernandes; Antónia Costa; Raquel Mota; Vera Paiva
Journal:  Case Rep Obstet Gynecol       Date:  2014-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.